Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Tripathy on Combination Strategies With CDK4/6 Inhibitors in HR+ Breast Cancer

September 10th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combination strategies with CDK4/6 inhibitors for the treatment of patients with hormone receptor (HR)-positive breast cancer.

Dr. Woodward on Regional Node Irradiation in Breast Cancer

September 6th 2018

Wendy A. Woodward, MD, PhD, professor and chief, Clinical Breast Radiotherapy Service, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses regional nodal irradiation for the treatment of patients with breast cancer.

Dr. Murthy on De-Escalation Strategies in HER2-Positive Breast Cancer

September 6th 2018

Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses de-escalation strategies for patients with HER2-positive breast cancer.

Dr. Arun on Immunogenicity in Triple-Negative Breast Cancer

September 5th 2018

Banu Arun, MD, professor in the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses immunogenicity in triple-negative breast cancer (TNBC).

ASCO Endorses Complementary Therapy Guidelines for Patients With Breast Cancer

August 31st 2018

In an effort to address strategies that many patients with cancer are adopting, ASCO has endorsed recommendations regarding the use of complementary therapies to manage symptoms and adverse effects of breast cancer treatment.

Dr. Tolaney Discusses Unmet Needs in ER+ Breast Cancer

August 31st 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses unmet needs in the treatment of patients with estrogen receptor (ER)-positive breast cancer.

Dr. Krop on the Impact of Recent Advances in Breast Cancer

August 30th 2018

Ian E. Krop, MD, PhD, chief, Breast Oncology, Susan F. Smith Center for Women’s Cancers, clinical research director, Breast Oncology Center, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the impact of recent advances in breast cancer.

Dr. Jhaveri Discusses a Basket Trial of Taselisib in Solid Tumors

August 29th 2018

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a basket trial of taselisib in patients with PIK3CA-mutated locally advanced or metastatic solid tumors.

Ellis Examines CDK4/6 Inhibitor Use in HR+ Breast Cancer

August 29th 2018

Matthew J. Ellis, MD, PhD, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive breast cancer.

Biomarkers, PARP Inhibitors Vital for Personalized Treatment in Breast Cancer Subtypes

August 29th 2018

Banu K. Arun, MD, discusses the challenge of treating patients with TNBC and BRCA1-related breast cancers, the value of genotyping, and what she hopes to see in future trial results.

Dr. Wang on Genomic Analysis of Breast Cancer Risk in Pediatric Cancer Survivors

August 29th 2018

Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses a genomic analysis of breast cancer risk in pediatric cancer survivors.

Adjuvant Trials Demonstrate High Clinical Impact in Breast Cancer

August 28th 2018

Maryam Nemati Shafaee, MD, discusses the pivotal trials in breast cancer that were reported at the 2018 ASCO Annual Meeting.

Dr. Yee Discusses the Categorization of Triple-Negative Breast Cancer

August 28th 2018

Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplant, medical oncologist, University of Minnesota, discusses the categorization of patients with triple-negative breast cancer.

Tolaney Discusses Developments Across Breast Cancer Subtypes

August 28th 2018

Sara M. Tolaney, MD, MPH, discusses developments in the treatment paradigms for patients with HR-positive or HER2-positive breast cancer.

Dr. Yardley Discusses Data With Talazoparib in Breast Cancer

August 27th 2018

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses data with talazoparib in breast cancer.

Dr. Sparano Discusses Unmet Needs in Metastatic Breast Cancer

August 27th 2018

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, Montefiore Medical Center, discusses unmet needs in metastatic breast cancer.

Dr. Formenti on the Role of the Immune System in Cancer Treatment

August 24th 2018

Silvia Chiara Formenti, MD, chair, Department of Radiation Oncology, Weill Cornell, associate director, Meyer Cancer Center, radiation oncologist-in-chief, NewYork-Presbyterian Hospital, discusses the role of the immune system in cancer treatment.

Dr. Tripathy on Frontline Endocrine Therapies in HR+ Breast Cancer

August 23rd 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses frontline endocrine therapies for patients with hormone receptor (HR)-positive breast cancer.

Dr. Borgen on Deciding Factors of Lymph Node Dissection in Breast Cancer

August 23rd 2018

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses important factors of deciding which patients with breast cancer need axillary lymph node dissection.

Alpelisib Improves PFS in PIK3CA+ Advanced Breast Cancer

August 23rd 2018

Combining Alpelisib (BYL719) with fulvestrant improved progression-free survival versus fulvestrant alone in postmenopausal women and men with HR-positive, HER2-negative, PIK3CA-mutant advanced or metastatic breast cancer that progressed after aromatase inhibitor treatment with or without a CDK4/6 inhibitor, meeting the primary endpoint of the phase III SOLAR-1 trial.